Status:
COMPLETED
An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.
Lead Sponsor:
Solvay Pharmaceuticals
Conditions:
Advanced Stage Parkinson's Disease
Eligibility:
All Genders
30+ years
Phase:
PHASE3
Brief Summary
This study is a multicenter, 9 months, open label extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.002 study.
Eligibility Criteria
Inclusion
- Inclusion Criteria Patients who have completed S308.3.002 trial Exclusion Criteria Patients with medically relevant abnormal findings (ECG, physical examination, Aes) at end of the maintenance phase (visit M6, week 24) of study S308.3.002
Exclusion
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2009
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT00407095
Start Date
August 1 2007
End Date
May 1 2009
Last Update
September 13 2010
Active Locations (87)
Enter a location and click search to find clinical trials sorted by distance.
1
S308.3.007 Site # 220
La Jolla, California, United States
2
S308.3.007 Site # 211
San Francisco, California, United States
3
S308.3.007 Site # 214
Fort Lauderdale, Florida, United States
4
S308.3.007 Site # 218
Gainsville, Florida, United States